Sign in
4

Changes in Ownership

Kalaris Therapeutics, Inc. Filed Acc 0001209191-23-056313

Chief Executive Officer sold 7,071 shares at an average $1.67 ($11,794)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Brainard Diana · Chief Executive Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2023-11-17 Sale : show line 1 in the form 10b5-1 −2,689 $1.63 $4,386 879,288 D
2023-11-20 Sale : show line 2 in the form 10b5-1 −4,382 $1.69 $7,408 874,906 D
Open-market sales · 7,071 sh · avg $1.67 · $11,794
Loading xslF345X05/doc4.xml…